Clinical Trials Logo

Clinical Trial Summary

Pancreatic cancer is associated with an extremely poor prognosis, reflected by a 5-y survival probability of less than 5% when all stages are combined. At present, only approximately 10%-20% of patients are considered candidates for curative resection. The majority of patients (50%-60%) are present with metastatic disease, and substantial number of patients (approximately 30%-40%) are considered ''locally advanced'' at the time of diagnosis.

Replication-competent Adenovirus-mediated Double Suicide Gene Therapy (Theragene®,Ad5-yCD/mutTKSR39rep-ADP) showed an anti-cancer effect in patients with prostatic cancer in phase I study. From the experience of prostatic cancer, the safety of combination with standard chemotherapy with Theragene treatment is assessed in this study.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT02894944
Study type Interventional
Source Seoul National University Hospital
Contact Jin-Hyeok Hwang, MD PhD
Phone +82-31-787-7017
Status Recruiting
Phase Phase 1
Start date August 2016
Completion date July 2018

See also
  Status Clinical Trial Phase
Recruiting NCT03153410 - Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Early Phase 1
Recruiting NCT03300921 - A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Phase 1
Recruiting NCT03756597 - PAN-study: Pan-Cancer Early Detection Study (PAN)
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*1101 Patients Phase 1/Phase 2
Not yet recruiting NCT03524677 - Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Borderline Resectable Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis
Not yet recruiting NCT03634332 - Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC Phase 2
Recruiting NCT03054987 - Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction N/A
Recruiting NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Recruiting NCT02919787 - Norwegian Pancreatic Cancer Trial (NorPACT) - 1 Phase 2/Phase 3
Recruiting NCT02743975 - Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma Phase 1/Phase 2
Recruiting NCT02869802 - Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
Recruiting NCT02954302 - Proximal Roux-en-y Gastrojejunal Anastomosis on Delayed Gastric Emptying After Pylorus-resecting Pancreaticoduodenectomy N/A
Recruiting NCT02541370 - Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133 Phase 1
Active, not recruiting NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Active, not recruiting NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1
Active, not recruiting NCT02551991 - Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma Phase 1/Phase 2
Terminated NCT02651727 - Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects Phase 1
Recruiting NCT02424279 - Invasive Treatment of Pain Associated With Pancreatic Cancer on Different Levels of WHO Analgesic Ladder N/A
Terminated NCT02242409 - Study of Gemcitabine and Abraxane for Pancreas Cancer Phase 2
Completed NCT02245217 - Multi-Tracer PET Prediction and Assessment of Response to Gemcitabine in Pancreatic Cancer Patients N/A